Jennifer Murdock1
John Nguyen2
Brady J. Hurtgen3Cathy Andorfer3John Walsh3Andrea Lin3Christopher Tubbs3
Kristine Erickson3*
Kimberly Cockerham4- 1Jennifer Murdock MD, PLLC, Miami, FL, United States
- 2School of Medicine, West Virginia University, Morgantown, WV, United States
- 3Tourmaline Bio, Inc., New York, NY, United States
- 4Department of Surgery, Sharp Grossmont Hospital for Neuroscience, La Mesa, CA, United States
A Correction on
The role of IL-6 in thyroid eye disease: an update on emerging treatments
By Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, Tubbs C, Erickson K and Cockerham K (2025) Front. Ophthalmol. 5:1544436. doi: 10.3389/fopht.2025.1544436
Author Jennifer Murdock was erroneously assigned to affiliation “1Oculofacial Plastic Surgery, Miami, FL, United States, and 2Thrive Health, West Vancouver, BC, Canada” instead of “1Jennifer Murdock MD, PLLC, Miami, FL, United States”. This affiliation has now been updated for author Jennifer Murdock.
The conflict of interest statement has been corrected to: AL, BH, CA, CT, JW, and KE are employees of Tourmaline Bio, Inc. JM is a medical director for Thrive Health, which administers IV infusions of teprotumumab, was a consultant for Horizon/Amgen until September 2023, and has a CDA with Tourmaline Bio, Inc. for planning internal consulting and education. JM is also the CEO of Jennifer Murdock MD, PLLC. KC is a consultant and principal investigator for Horizon/Amgen, Viridian, Acelyrin, Genentech/Roche, Immunovant, ArgenX, and Tourmaline Bio, Inc. JN has received research funding from Tourmaline Bio, Inc.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: IL-6, IL-6R, thyroid eye disease (TED), Graves’ ophthalmopathy, Graves’ orbitopathy, Graves’ disease, thyroid-associated orbitopathy (TAO)
Citation: Murdock J, Nguyen J, Hurtgen BJ, Andorfer C, Walsh J, Lin A, Tubbs C, Erickson K and Cockerham K (2025) Correction: The role of IL-6 in thyroid eye disease: an update on emerging treatments. Front. Ophthalmol. 5:1641164. doi: 10.3389/fopht.2025.1641164
Received: 04 June 2025; Accepted: 10 June 2025;
Published: 16 July 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Murdock, Nguyen, Hurtgen, Andorfer, Walsh, Lin, Tubbs, Erickson and Cockerham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kristine Erickson, a2VyaWNrc29uQHRvdXJtYWxpbmViaW8uY29t